Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 13/20 | 0.67 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855447 | 0.91 | NPC1L1 (0.70) | NPC1L1OPRM1OPRK1BDKRB2DDR1 | |
| SCHEMBL17140929 | 0.90 | NPC1L1 (0.65) | NPC1L1OPRL1OPRM1OPRK1BDKRB2 | |
| SCHEMBL8893884 | 0.90 | NPC1L1 (0.56) | NPC1L1OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL20187144 | 0.89 | NPC1L1 (0.66) | NPC1L1OPRL1OPRM1OPRK1DDR1 | |
| SCHEMBL318821 | 0.88 | NPC1L1 (0.57) | NPC1L1OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL20187150 | 0.87 | NPC1L1 (0.64) | NPC1L1DDR1 | |
| SCHEMBL20187031 | 0.87 | OPRL1 (0.67) | NPC1L1OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL20187070 | 0.87 | NPC1L1 (0.66) | NPC1L1BDKRB2DDR1 | |
| SCHEMBL5563023 | 0.86 | NPC1L1 (0.64) | NPC1L1OPRL1OPRM1OPRK1BDKRB2 | |
| SCHEMBL20187219 | 0.85 | NPC1L1 (0.74) | NPC1L1DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263608-B2 | Melanocortin receptor-specific spiro-piperidine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010037081-A1 | MELANOCORTIN RECEPTOR-SPECIFIC SPIRO-PIPERIDINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-5610142-A | Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids | SCIOS INC. (US) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | MC1R, MC5R, MC3R | NPC1L1 3833/4885OPRL1 12/4885OPRM1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.